Search research articles
Contact Us
Filters
Showing results (81-90 of 106) with videos related to
Page
of 11
Sort By:
Aktuelle Urologie
|
May 21, 2021
H Rexer, A Stenzl, M Bögemann
Aktuelle Urologie
|
August 27, 2020
H Rexer, J Bedke, A Merseburger
Der Urologe. Ausg. A
|
October 6, 2017
[Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO]
H Rexer, M Graefen, A Merseburger, et al.
Der Urologe. Ausg. A
|
October 8, 2016
[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO]
H Rexer, M Retz, P Albers
Aktuelle Urologie
|
March 22, 2019
H Rexer, P Hammerer, A Merseburger
Aktuelle Urologie
|
August 8, 2018
H Rexer, C-H Ohlmann, J Gschwend
Der Urologe. Ausg. A
|
August 6, 2017
[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO]
H Rexer, C-H Ohlmann, J Gschwend, et al.
Aktuelle Urologie
|
November 24, 2020
H Rexer, M-O Grimm, T Steiner
Der Urologe. Ausg. A
|
March 29, 2017
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)]
H Rexer, C-H Ohlmann, M Retz
Aktuelle Urologie
|
February 2, 2018
H Rexer, C-H Ohlmann, M Retz
Page
of 11
Search research articles
Search
Showing results (81-90 of 106) with videos related to
Sort By:
Page
of 11
Aktuelle Urologie
|
May 21, 2021
H Rexer, A Stenzl, M Bögemann
Aktuelle Urologie
|
August 27, 2020
H Rexer, J Bedke, A Merseburger
Der Urologe. Ausg. A
|
October 6, 2017
[Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO]
H Rexer, M Graefen, A Merseburger, et al.
Der Urologe. Ausg. A
|
October 8, 2016
[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO]
H Rexer, M Retz, P Albers
Aktuelle Urologie
|
March 22, 2019
H Rexer, P Hammerer, A Merseburger
Aktuelle Urologie
|
August 8, 2018
H Rexer, C-H Ohlmann, J Gschwend
Der Urologe. Ausg. A
|
August 6, 2017
[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO]
H Rexer, C-H Ohlmann, J Gschwend, et al.
Aktuelle Urologie
|
November 24, 2020
H Rexer, M-O Grimm, T Steiner
Der Urologe. Ausg. A
|
March 29, 2017
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)]
H Rexer, C-H Ohlmann, M Retz
Aktuelle Urologie
|
February 2, 2018
H Rexer, C-H Ohlmann, M Retz
Page
of 11